EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Year-over-year free cash flow growth rate
Percentile
P46
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -9.78% |
| Q3 2025 | 5.73% |
| Q2 2025 | -19.50% |
| Q1 2025 | -47.37% |
| Q4 2024 | 10.76% |
| Q3 2024 | -92.63% |
| Q2 2024 | 34.87% |
| Q1 2024 | -34.90% |
| Q4 2023 | -41.76% |
| Q3 2023 | -129.89% |
| Q2 2023 | 426.96% |
| Q1 2023 | -31.47% |
| Q4 2022 | 8.10% |
| Q3 2022 | 25.89% |
| Q2 2022 | 4.76% |
| Q1 2022 | -21.83% |
| Q4 2021 | -110.51% |
| Q3 2021 | 25.08% |
| Q2 2021 | 30.01% |
| Q1 2021 | -364.76% |
| Q4 2020 | 465.77% |
| Q3 2020 | 119.58% |
| Q2 2020 | 68.54% |
| Q1 2020 | -42.37% |
| Q4 2019 | 22.20% |
| Q3 2019 | 13.78% |
| Q2 2019 | -26.75% |
| Q1 2019 | -24.65% |
| Q4 2018 | 8.69% |
| Q3 2018 | -93.85% |
| Q2 2018 | -27.12% |
| Q1 2018 | 6.68% |
| Q4 2017 | 14.39% |
| Q3 2017 | -31.76% |
| Q2 2017 | -0.42% |
| Q1 2017 | 9.07% |
| Q4 2016 | 22.70% |
| Q3 2016 | -47.64% |
| Q2 2016 | -1.38% |
| Q1 2016 | -35.45% |